Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX) have received an average rating of “Buy” from the eight ratings firms that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $39.14.

CDTX has been the subject of several research reports. Needham & Company LLC reiterated a “buy” rating and set a $35.00 price objective on shares of Cidara Therapeutics in a research note on Friday, March 7th. WBB Securities boosted their price objective on Cidara Therapeutics from $40.00 to $45.00 and gave the stock a “strong-buy” rating in a research note on Thursday, December 5th. Citizens Jmp initiated coverage on Cidara Therapeutics in a research note on Wednesday. They set an “outperform” rating and a $46.00 price objective for the company. Cantor Fitzgerald upgraded Cidara Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 5th. Finally, Citigroup initiated coverage on Cidara Therapeutics in a research note on Wednesday. They set an “outperform” rating for the company.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CDTX. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Cidara Therapeutics during the 4th quarter worth approximately $56,000. Point72 Asset Management L.P. acquired a new position in Cidara Therapeutics in the fourth quarter valued at approximately $165,000. OMERS ADMINISTRATION Corp acquired a new position in Cidara Therapeutics in the fourth quarter valued at approximately $339,000. Jane Street Group LLC acquired a new position in Cidara Therapeutics in the fourth quarter valued at approximately $342,000. Finally, Boothbay Fund Management LLC acquired a new position in Cidara Therapeutics in the fourth quarter valued at approximately $419,000. 35.82% of the stock is currently owned by institutional investors and hedge funds.

Cidara Therapeutics Stock Up 9.5 %

Shares of Cidara Therapeutics stock opened at $23.00 on Thursday. Cidara Therapeutics has a twelve month low of $10.00 and a twelve month high of $28.42. The business has a 50-day moving average price of $22.35 and a 200 day moving average price of $17.64. The firm has a market cap of $162.08 million, a PE ratio of -0.90 and a beta of 0.88.

Cidara Therapeutics (NASDAQ:CDTX) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($5.38) earnings per share for the quarter, missing the consensus estimate of ($5.28) by ($0.10). Cidara Therapeutics had a negative net margin of 289.05% and a negative return on equity of 69.64%. On average, sell-side analysts expect that Cidara Therapeutics will post -8.74 EPS for the current year.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.